Vertex Pharmaceuticals, Inc. (VRTX)
556.69
+9.04
(+1.65%)
USD |
NASDAQ |
Sep 02, 16:00
556.75
+0.06
(+0.01%)
After-Hours: 19:39
Vertex Pharmaceuticals Research and Development Expense (TTM) : 3.907B for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 3.907B |
| March 31, 2026 | 3.891B |
| December 31, 2025 | 3.929B |
| September 30, 2025 | 3.954B |
| June 30, 2025 | 3.868B |
| March 31, 2025 | 8.305B |
| December 31, 2024 | 8.171B |
| September 30, 2024 | 7.994B |
| June 30, 2024 | 7.965B |
| March 31, 2024 | 3.446B |
| December 31, 2023 | 3.669B |
| September 30, 2023 | 3.539B |
| June 30, 2023 | 3.351B |
| March 31, 2023 | 3.117B |
| December 31, 2022 | 2.630B |
| September 30, 2022 | 2.631B |
| June 30, 2022 | 2.450B |
| March 31, 2022 | 3.195B |
| December 31, 2021 | 3.048B |
| September 30, 2021 | 2.823B |
| June 30, 2021 | 2.823B |
| March 31, 2021 | 1.837B |
| December 31, 2020 | 1.830B |
| September 30, 2020 | 1.843B |
| June 30, 2020 | 1.905B |
| Date | Value |
|---|---|
| March 31, 2020 | 1.864B |
| December 31, 2019 | 1.755B |
| September 30, 2019 | 1.712B |
| June 30, 2019 | 1.487B |
| March 31, 2019 | 1.445B |
| December 31, 2018 | 1.416B |
| September 30, 2018 | 1.285B |
| June 30, 2018 | 1.410B |
| March 31, 2018 | 1.362B |
| December 31, 2017 | 1.325B |
| September 30, 2017 | 1.266B |
| June 30, 2017 | 1.084B |
| March 31, 2017 | 1.065B |
| December 31, 2016 | 1.048B |
| September 30, 2016 | 1.110B |
| June 30, 2016 | 1.084B |
| March 31, 2016 | 1.036B |
| December 31, 2015 | 996.17M |
| September 30, 2015 | 887.20M |
| June 30, 2015 | 831.86M |
| March 31, 2015 | 832.78M |
| December 31, 2014 | 856.14M |
| September 30, 2014 | 904.29M |
| June 30, 2014 | 941.98M |
| March 31, 2014 | 939.65M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Gilead Sciences, Inc. | 5.943B |
| Alnylam Pharmaceuticals, Inc. | 1.509B |
| Sionna Therapeutics, Inc. | 72.04M |
| Regeneron Pharmaceuticals, Inc. | 5.748B |
| Biogen, Inc. | 1.736B |